FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Immunovia AB's FCF Yield % or its related term are showing as below:
IMMVF'
s FCF Yield % Range Over the Past 10 Years
Min: -1126.01 Med: -6.73 Max: -1.04
Current: -58.94
During the past 13 years, the highest FCF Yield % of Immunovia AB was -1.04%. The lowest was -1126.01%. And the median was -6.73%.
IMMVF's FCF Yield % is ranked worse than 91.12% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.475
vs IMMVF: -58.94
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Immunovia AB FCF Yield % Related Terms
Immunovia AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Immunovia AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Immunovia AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Immunovia AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (IMMVF) has a FCF Yield % of -58.94 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #195 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 91.1%.
Is Immunovia AB's FCF Yield % too high?
Immunovia AB's current FCF Yield % is -58.94. Based on the distribution chart, Immunovia AB ranks #195 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #195 out of 214 companies for FCF Yield %. This places Immunovia AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Immunovia AB and its competitors. Immunovia AB's current FCF Yield % is -58.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current FCF Yield % of -58.94. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current FCF Yield % is -58.94. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current FCF Yield % is -58.94 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
FCF Yield %: -58.94
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for IMMVF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
